CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+50.84%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$1.14B
AUM Growth
+$1.14B
(+34%)
Cap. Flow
+$97.3M
Cap. Flow
% of AUM
8.5%
Top 10 Holdings %
Top 10 Hldgs %
62.98%
Holding
38
New
8
Increased
7
Reduced
7
Closed
6
Top Buys
| 1 |
Arvinas
ARVN
|
$41.2M |
| 2 |
Spyre Therapeutics
SYRE
|
$38M |
| 3 |
Nuvalent
NUVL
|
$37M |
| 4 |
Pharvaris
PHVS
|
$22.4M |
| 5 |
C4 Therapeutics
CCCC
|
$21.5M |
Top Sells
| 1 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$40.5M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
$24.1M |
| 3 |
IDEAYA Biosciences
IDYA
|
$20.9M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$14.9M |
| 5 |
Cabaletta Bio
CABA
|
$14.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $131M | 11.41% | 4,747,373 +319,301 | +7% | +$8.78M |
|
2
Xenon Pharmaceuticals
XENE
$2.98B
| $99.8M | 8.72% | 2,167,793 +322,793 | +17% | +$14.9M |
|
|
3
Nuvalent
NUVL
$5.52B
| $98M | 8.56% | 1,331,037 +502,259 | +61% | +$37M |
|
4
Vera Therapeutics
VERA
$1.38B
| $83.8M | 7.32% | 5,450,000 | – | – |
|
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $71.3M | 6.23% | 1,550,000 -525,000 | -25% | -$24.1M |
|
6
Vaxcyte
PCVX
$4B
| $69.1M | 6.04% | 1,100,000 | – | – |
|
|
7
Cabaletta Bio
CABA
$133M
| $43.1M | 3.77% | 1,900,000 -625,753 | -25% | -$14.2M |
|
8
Immunovant
IMVT
$2.56B
| $42.1M | 3.68% | 1,000,000 | – | – |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $41.9M | 3.66% | 1,924,074 -275,926 | -13% | -$6.01M |
|
|
10
Arvinas
ARVN
$568M
| $41.2M | 3.6% | +1,000,000 | New | +$41.2M |
|
|
11
Spyre Therapeutics
SYRE
$996M
| $40.5M | 3.54% | 1,884,084 +1,767,760 | +1,520% | +$38M |
|
12
Enliven Therapeutics
ELVN
$1.2B
| $40.2M | 3.51% | 2,901,816 | – | – |
|
13
Cogent Biosciences
COGT
$1.69B
| $32.7M | 2.86% | 5,566,026 | – | – |
|
|
ALPN
14
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $30.7M | 2.68% | 1,610,000 +285,000 | +22% | +$5.43M |
|
15
Soleno Therapeutics
SLNO
$3.6B
| $28.2M | 2.46% | 700,000 -187,500 | -21% | -$7.55M |
|
16
Celldex Therapeutics
CLDX
$1.47B
| $27.8M | 2.43% | 701,967 -4,698 | -0.7% | -$186K |
|
17
Celcuity
CELC
$2.17B
| $25.6M | 2.23% | 1,754,704 +60,563 | +4% | +$882K |
|
|
RYZB
18
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $23.9M | 2.08% | 383,638 +94,727 | +33% | +$5.89M |
|
|
19
Pharvaris
PHVS
$1.39B
| $22.4M | 1.96% | +800,000 | New | +$22.4M |
|
|
20
C4 Therapeutics
CCCC
$185M
| $21.5M | 1.88% | +3,800,000 | New | +$21.5M |
|
|
ABVX
21
Abivax
ABVX
$6.12B
| $20.3M | 1.77% | +1,895,003 | New | +$20.3M |
|
22
Nkarta
NKTX
$151M
| $18M | 1.57% | +2,730,000 | New | +$18M |
|
23
Kura Oncology
KURA
$686M
| $17.9M | 1.57% | 1,248,062 -151,938 | -11% | -$2.18M |
|
|
HARP
24
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $17.1M | 1.49% | +1,500,000 | New | +$17.1M |
|
25
Akero Therapeutics
AKRO
$3.74B
| $13.2M | 1.15% | 565,000 | – | – |
|